Clofazimine

Clofazimine

File:Clofazimine.svg
Clinical data
ATC code	J04BA01 (WHO)
Pharmacokinetic data
Elimination half-life	70 days
Identifiers
IUPAC name N,5-bis(4-chlorophenyl)-3- (1-methylethylimino)-5H-phenazin-2-amine
CAS Number	2030-63-9
PubChem CID	2794
DrugBank	APRD00278
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C27H22Cl2N4
Molar mass	473.396 g/mol

WikiDoc Resources for Clofazimine
Articles
Most recent articles on Clofazimine Most cited articles on Clofazimine Review articles on Clofazimine Articles on Clofazimine in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Clofazimine Images of Clofazimine Photos of Clofazimine Podcasts & MP3s on Clofazimine Videos on Clofazimine
Evidence Based Medicine
Cochrane Collaboration on Clofazimine Bandolier on Clofazimine TRIP on Clofazimine
Clinical Trials
Ongoing Trials on Clofazimine at Clinical Trials.gov Trial results on Clofazimine Clinical Trials on Clofazimine at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Clofazimine NICE Guidance on Clofazimine NHS PRODIGY Guidance FDA on Clofazimine CDC on Clofazimine
Books
Books on Clofazimine
News
Clofazimine in the news Be alerted to news on Clofazimine News trends on Clofazimine
Commentary
Blogs on Clofazimine
Definitions
Definitions of Clofazimine
Patient Resources / Community
Patient resources on Clofazimine Discussion groups on Clofazimine Patient Handouts on Clofazimine Directions to Hospitals Treating Clofazimine Risk calculators and risk factors for Clofazimine
Healthcare Provider Resources
Symptoms of Clofazimine Causes & Risk Factors for Clofazimine Diagnostic studies for Clofazimine Treatment of Clofazimine
Continuing Medical Education (CME)
CME Programs on Clofazimine
International
Clofazimine en Espanol Clofazimine en Francais
Business
Clofazimine in the Marketplace Patents on Clofazimine
Experimental / Informatics
List of terms related to Clofazimine

Clofazimine is a fat-soluble riminophenazine dye used in combination with rifampicin and dapsone as multidrug therapy (MDT) for the treatment of leprosy. It has been used investigationally in combination with other antimycobacterial drugs to treat Mycobacterium avium infections in AIDS patients. Clofazimine also has a marked anti-inflammatory effect and is given to control the leprosy reaction, erythema nodosum leprosum (ENL). (From AMA Drug Evaluations Annual, 1993, p1619).

History

Clofazimine, initially known as B663, was first synthesised in 1954 by a team led by Dr Vincent Barry at Trinity College, Dublin as an anti-tuberculosis drug. The drug proved ineffective against tuberculosis but in 1959 a researcher named Chang identified its effectiveness against leprosy. After clinical trials in Nigeria and elsewhere during the 1960s, some sponsored by the Swiss pharmaceutical company Geigy (today member of the Novartis group of drug producers), the product was launched in 1969 as Lamprene.

The U.S. government named Clofazimine an orphan drug in June 1986. Geigy gained FDA approval for the drug in December 1986.

Supply

Clofazimine is marketed under the trade name Lamprene® by Novartis. One of the only suppliers of Clofazimine Active Pharmaceutical Ingredient in the world is Sangrose Laboratories, located at Mavelikara in the southern Indian state of Kerala.

Metabolism

Clofazimine has a very long half life of about 70 days. Clofazimine produces pink to brownish skin pigmentation in 75-100% of patients within a few weeks.

External links

• Official FDA Drug Label
• RxList Clofazimine (most information taken from FDA)